Need more information?
Our dedicated team of Novartis representatives based throughout the UK are on hand to answer your local queries.
Image
Image
Cosentyx® (secukinumab) HCP resources
Cosentyx® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy.1
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.
Explore our resources designed to support Cosentyx initiation and ongoing maintenance for patients with plaque psoriasis.
Below you can find helpful resources for you and your patients. Please note that only the resources in the ‘Resources for patients’ section can be downloaded and shared with your Cosentyx patients. Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only.
Please share the following link to direct your patients who have been prescribed Cosentyx to a dedicated page that they can use to access all available patient resources:
Please note that these resources are designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.
Video
5 mins 56 secs
SensoReady® 150 mg
injection video
Video
- 15 Jul 2024
5 mins 56 secs
A short video showing you how to prepare and inject Cosentyx with the SensoReady® pen.
A short instructional video that demonstrates how to prepare and inject Cosentyx with the SensoReady® 150mg pen.
Video
6 mins 37 secs
UnoReady® 300 mg injection video
Video
- 15 Jul 2024
6 mins 37 secs
A short video showing you how to prepare and inject Cosentyx with the UnoReady® 300mg pen.
A short video showing you how to prepare and inject Cosentyx with the UnoReady® 300mg pen.
Video
15 mins 10 secs
Patient case studies with Dr Anthony Abdullah
Watch Dr Anthony Abdullah as he briefly discusses efficacy and safety profile data from key studies of Cosentyx. He also introduces three patient case studies and explains how Cosentyx was used to treat their moderate or severe psoriasis.
Article
2 mins
Digital dosing schedule
Digital dosing schedule
Image
Adult hidradenitis suppurativa digital patient pack
Adult hidradenitis suppurativa digital patient pack
PDF
Therapeutic indications1
Cosentyx is indicated for the treatment of moderate to severe PsO in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active PsA in adult patients (alone or in combination with MTX) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active AS in adults who have responded inadequately to conventional therapy; active nr-axSpA with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe HS (acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active ERA in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active JPsA in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1
AS, ankylosing spondylitis; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; ERA, enthesitis-related arthritis; HS, hidradenitis suppurativa; JPsA, juvenile psoriatic arthritis; MRI, magnetic resonance imaging; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, plaque psoriasis.
Reference
Cosentyx® (secukinumab) Summary of Product Characteristics.
UK | November 2025 | FA-11386156-1
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
